Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">rClone30</td><td class="align_center">rClone30-VP2L-chGM-CSF</td><td class="align_center">rClone30-VP2L</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">HA</td><td class="align_center">2<sup>9</sup></td><td class="align_center">2<sup>8</sup></td><td class="align_center">2<sup>9</sup></td></tr><tr><td class="align_left" colspan="4"><hr/></td></tr><tr><td class="align_left">lgEID<sub>50</sub>/0.1mL</td><td class="align_center">8</td><td class="align_center">7.6</td><td class="align_center">8</td></tr><tr><td class="align_left">MDT</td><td class="align_center">&gt;144</td><td class="align_center">&gt;144</td><td class="align_center">&gt;144</td></tr><tr><td class="align_left">ICPI</td><td class="align_center">0</td><td class="align_center">0</td><td class="align_center">0</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Biological characteristics of the parental and recombinant viruses.</div>

Transboundary and Emerging Diseases

tab4

Table 4

Table 4: Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease 